Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Other

Chiba University

Hajime Tsunoda

Yoshinori Sakuma

Satoshi Katayama

Kenzo Muramoto

Yoshimasa Machida

Mitsuaki Miyamoto

Richard Stephen John Clark

Shigeru Souda

Hiroshi Obaishi

Kouichi Katayama

Kouji Yamada

Isao Yamatsu

Tetsuya Kawahara

Kazuo Okano

Shinya Abe

Hiroyuki Yoshimura

Shuhei Miyazawa

Richard S Clark

Koukichi Harada

Naoyuki Shimomura

Toshio Imai

Osamu Asano

Kenichi Chiba

Yoshimori Sakuma

Mark Spyvee

Fabian Gusovsky

Yimin Jiang

Hiroshi Shirota

Xiang-Yi Li

Toshihiko Kaneko

Yoshimasa Sakamoto

Miyuki Nishimura

Norihito Ohi

Hiromitsu Yokohama

Yoshikazu Kuboi

Keiko Yamaguchi

Luigi Grasso

Jean-Christophe P Harmange

Takeshi Suzuki

Seiichi Kobayashi

Kouichi Kikuchi

Motohiro Soejima

Ieharu Hishinuma

Satoshi Yamamoto

Tomohiro Matsushima

Naoki Yoneda

Takashi Inoue

Boris M Seletsky

Heather Davis

Atsushi Inoue

Wanjun Zheng

Makoto Kotake

Jared Spidel

Yoshiyuki Kawakami

André Lescarbeau

Hong Du

Tatsuo Horizoe

Ryoichi Hashida

Isao Tanaka

Bruce Decosta

Yoshiharu Mizui

Takashi Mori

Toru Horie

Masaki Goto

Masanori Fujita

Yoshihito Eguchi

John (Yuan) Wang

Tetsu Kawano

Hideki Sakurai

Marc Pesant

Akifumi Kimura

Ye Yao

Takatoshi Kawai

Yong-Chun Shen

Jane Daun

Lynda Tremblay

Kenichi Kusube

Yan (Janet) Zhao

Megumi Kawada

Roch Boivin

James Bradford Kline

Jesse Chow

Charles-André Lemelin

Toshinori Nakayama

Fumihiro Ozaki

Takashi Yamanaka

Atsushi Kamada

Masayoshi Ohkuro

Tohru Arai

Koji Hayashizaki

Ray Wood

Toshifumi Hirayama

Motoko Kimura

Osamu Takenaka

Jiro Sonoda

Jungo Kakuta

Ryu Gejima

Hirsohi Shirota

Daisuke Tokita

Richar S Clark

The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Anti-MYL9 antibody

The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

Neutralizing anti-CCL20 antibodies

The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

Methods for detecting Th1 cells

Nucleic acids encoding neutralizing anti-CCL20 antibodies

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

The present invention provides compositions comprising compounds having formula (I): 

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.

Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Growing community of inventors

Tsukuba, Japan

Kenzo Muramoto